Bio-reconfigurable Electronic Platform for Multiplex Detection of Viral Respiratory Pathogens

Active, not recruiting

• Conditions: COVID 19

• Registration Number: NCT06702540
• Lead Sponsor: IRCCS San Raffaele

Brief Summary

This project focuses on developing a cutting-edge electronic biosensor platform for highly sensitive and specific detection of target biomolecules, with initial applications targeting SARS-CoV-2 detection. The system operates on impedance measurement between microelectrodes, utilizing lock-in mode for unparalleled resolution (1 ppm). Enhanced signal detection is achieved via functionalized polystyrene microbeads that amplify impedance changes, building on prior success in Dengue virus antibody detection.

Key innovations include Differential Impedance Sensing across multiple channels for real-time comparative analysis of various targets, and a biosensor chip modified with DMA-based functional polymers for optimal probe immobilization and target interaction. The biosensor integrates with a pre-existing microfluidic system and supports whole-virus detection using DNA-labelled antibodies against SARS-CoV-2 spike protein, coupled with complementary oligonucleotide-functionalized beads. This strategy is complemented by antigen-specific detection for practical applications such as point-of-care testing in pharmacies.

The project includes a retrospective study analyzing anonymized respiratory and plasma samples from a COVID-19 biobank to validate the platform's sensitivity in detecting viral particles. These efforts aim to advance diagnostic technologies for respiratory infections with a focus on safety, scalability, and versatility.

Detailed Description

The project stands on the development of an electronic platform performing the measurement of the impedance variation between microelectrodes upon the capture of the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals (1 ppm has been demonstrated by POLIMI on other applications). To enhance the electronic signal, polystyrene microbeads, properly functionalized with oligonucleotides or antibodies, are used to link the target and increase the impedance variation as demonstrated by proponents in the successful detection of antibodies against Dengue virus. To address multiple sensing sites in parallel on the same biosensor chip, allowing real-time comparative analysis on different targets from the same biological sample for augmented detection sensitivity and control, a custom-made electronic platform will be developed to perform Differential Impedance Sensing (i.e., direct comparison between the target sensor and a reference) on multiple channels. The biosensor chip, made of borosilicate with gold microelectrodes, features a specific modification of its surface with functional polymers (a family of N,N-dimethylacrylamide -DMA-based polymers) developed by CNR that form a nanometric hydrophilic film on the chip surface. The functional groups of these copolymers allow the covalent immobilization of the probe preserving its active structure, proper spatial distance, orientation and density, favoring the interaction with the target. The biosensor chip will be integrated into the microfluidic system already available in the group.

SARS-CoV-2 will be targeted with challenging strategies. First, we plan to capture the entire virus in solution using DNA-labelled antibodies directed against the SARS-CoV-2 spike protein.

The sensor area, spotted with oligonucleotide probes complementary to the DNA sequence linked to the antibody, will interact with the DNA-labelled antibodies which have decorated the entire surface of the virus. To increase the impedance variation of the platform polystyrene beads will be used: in particular, they will be modified with the oligonucleotide complementary to that linked to the antibody which have captured the virus. This entire-virus detection methodology, combining the DNA-directed capture of the antigens together with a high sensitivity platform for Differential Impedance Sensing, is absolutely new and expected to be successful based upon the results already achieved by the proponents in the detection of the antibodies in the human blood of persons infected by Dengue virus. In parallel, we intend to extend the use of the electronic platform also to the detection of viral antigens, i.e. Spike protein S or nucleocapside protein N. The use of antigens for the diagnosis of the infection instead of the entire virus, may lead to important practical dropouts as it does not necessitate any particular safety requirement, thus allowing the test to be performed in any location, in particular pharmacies or medical clinics similarly to standard antigenic lateral flow tests.

This is a retrospective monocenter study to test respiratory samples to evaluate the analytical sensitivity of the platform being developed in the project PRIN Prot. 2022EJL28B. The samples are completed anonymized and the samples analyses are performed in order to check the ability of the device to reveal the presence of viral particles in biological matrix such as respiratory samples or, when necessary for set up of instruments, plasma randomized and anonymized samples. No patients or use of clinical data will be involved for the study, but only used the samples stored in the San Raffaele institutional COVID-19 clinical-biological biobank (COVID-BioB, NCT04318366). The samples used for the study were collected during the period 19/03/2020 - 31/05/2024.

Study Timeline

• Study Start: 2020-03-19
• Primary Completion: 2024-05-31
• Status Verified: 2024-11
• Study First Submitted: 2024-11-18
• Study First Submitted QC: 2024-11-21
• Last Update Submitted: 2024-11-21
• Study First Posted: 2024-11-25
• Last Update Posted: 2024-11-25
• Study Completion: 2025-09-28

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

• Samples tested for respiratory viruses, stored at the San Raffaele institutional COVID-19 clinical-biological biobank (COVID-BioB, NCT04318366).

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Validation of the biosensor platform with nasopharyngeal swabs	12 months	Real-time impedance measurement in randomized respiratory samples to detect respiratory viruses

Trial Locations

Locations (1)

IRCCS San Raffaele; 🇮🇹 Milan, Italy